Kenneth P. H. Pritzker

Gründer bei Rna Diagnostics, Inc.

Health Services

Health Technology

Profil

Kenneth P.
H.
Pritzker is the founder and director of RNA Diagnostics, Inc. which is founded in 2010.
He also held a director position at CareRx Corp.
in 2009.

Aktive Positionen von Kenneth P. H. Pritzker

Unternehmen	Position	Beginn
Rna Diagnostics, Inc. Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada.	Gründer	01.01.2010

Alle aktiven Positionen von Kenneth P. H. Pritzker

Ehemalige bekannte Positionen von Kenneth P. H. Pritzker

Unternehmen	Position	Ende
CARERX CORPORATION	Direktor/Vorstandsmitglied	25.06.2009

Sehen Sie sich die Erfahrung von Kenneth P. H. Pritzker im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Kenneth P. H. Pritzker im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen	1
CARERX CORPORATION	Health Services

Private Unternehmen	1
Rna Diagnostics, Inc. Rna Diagnostics, Inc. Medical SpecialtiesHealth Technology Rna Diagnostics, Inc. operates as a cancer diagnostics company which builds a platform of prognostic biomarker tools to help improve the lives of patients undergoing chemotherapy. The firm develops prognostic biomarker tools to improve the lives of women undergoing chemotherapy for breast cancer. It provides The RNA Disruption Assay (RDA), which provides physicians with an evaluation of how individual patients are responding to chemotherapy. The company was founded by Kenneth P. H. Pritzker in 2010 and is headquartered in Toronto, Canada.	Health Technology